Several analysts have recently updated their ratings and price targets for Strongbridge Biopharma PLC (NASDAQ: SBBP):

  • 10/11/2017 – Strongbridge Biopharma PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 10/4/2017 – Strongbridge Biopharma PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “
  • 10/2/2017 – Strongbridge Biopharma PLC was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 9/28/2017 – Strongbridge Biopharma PLC was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Strongbridge Biopharma PLC is a biopharmaceutical company which develops, acquires and commercializes product candidates that target rare diseases. Its product candidate consists of COR-003, is a cortisol inhibitor, for the treatment of endogenous Cushing’s syndrome, COR-004 and COR-005 to treat acromegaly, BP-2001, the treatment of diabetes which are in different clinical trial. Strongbridge Biopharma PLC is based in Trevose, Pennsylvania. “

Strongbridge Biopharma PLC (SBBP) opened at 6.25 on Thursday. The company’s 50-day moving average is $6.72 and its 200-day moving average is $5.75. Strongbridge Biopharma PLC has a 52-week low of $2.00 and a 52-week high of $8.85. The firm’s market capitalization is $220.84 million.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The business had revenue of $1.53 million for the quarter, compared to analysts’ expectations of $0.84 million. On average, analysts predict that Strongbridge Biopharma PLC will post ($2.28) EPS for the current year.

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.